

CONSORT 2025 checklist of information to include when reporting a randomised trial			
Section/topic	No	CONSORT 2025 checklist item description	Page Number
Title and abstract			
Title and structured abstract	1a	Identification as a randomised trial	Page 1 (Title); Page 2, Lines 39-42
	1b	Structured summary of the trial design, methods, results, and conclusions	Page 2, Lines 32-63
Open science			
Trial registration	2	Name of trial registry, identifying number (with URL) and date of registration	Page 1, Lines 28-29 ; Page 4, Lines 132-134
Protocol and statistical analysis plan	3	Where the trial protocol and statistical analysis plan can be accessed	Not applicable
Data sharing	4	Where and how the individual de-identified participant data (including data dictionary), statistical code and any other materials can be accessed	Page 16, Lines 555-559
Funding and conflicts of interest	5a	Sources of funding and other support (eg, supply of drugs), and role of funders in the design, conduct, analysis and reporting of the trial	Page 1 (cover page); Page 16, Lines 566—567
	5b	Financial and other conflicts of interest of the manuscript authors	Page 1 (cover page); Page 16, Lines 564-565
Introduction			
Background and rationale	6	Scientific background and rationale	Page 3, Lines 74-110
Objectives	7	Specific objectives related to benefits and harms	Page 3, Lines 107-110
Methods			
Patient and public involvement	8	Details of patient or public involvement in the design, conduct and reporting of the trial	Not applicable
Trial design	9	Description of trial design including type of trial (eg, parallel group, crossover), allocation ratio, and framework (eg, superiority, equivalence, non-inferiority, exploratory)	Page 4, Lines 112-122
Changes to trial protocol	10	Important changes to the trial aker it commenced including any outcomes or analyses that were not prespecified, with reason	Not applicable
Trial setting	11	Settings (eg, community, hospital) and locations (eg, countries, sites) where the trial was conducted	Page5, Lines 155-173
Eligibility criteria	12a	Eligibility criteria for participants	Page 4, Lines 128-130
	12b	If applicable, eligibility criteria for sites and for individuals delivering the interventions (eg, surgeons, physiotherapists)	Not applicable
Intervention and comparator	13	Intervention and comparator with sufficient details to allow replication. If relevant, where additional materials describing the intervention and comparator (eg, intervention manual) can be accessed	Pages 5-6, Lines 151-199
Outcomes	14	Prespecified primary and secondary outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome	Pages 7-8, Lines 243-273
Harms	15	How harms were defined and assessed (eg, systematically, non-systematically)	Not applicable
Sample size	16a	How sample size was determined, including all assumptions supporting the sample size calculation	Page 4, Lines 135-146
	16b	Explanation of any interim analyses and stopping guidelines	Not applicable
Randomisation:			
Sequence generation	17a	Who generated the random allocation sequence and the method used	Pages 5, Lines 147-153
	17b	Type of randomisation and details of any restriction (eg, stratification, blocking and block size)	Page 5, Lines 147-153
Allocation concealment mechanism	18	Mechanism used to implement the random allocation sequence (eg, central computer/telephone; sequentially numbered, opaque, sealed containers), describing any steps to conceal the sequence until interventions were assigned	Pages 5, Lines 147-153
Implementation	19	Whether the personnel who enrolled and those who assigned participants to the interventions had access to the random allocation sequence	Page 5, Lines 155-173
Blinding	20a	Who was blinded aker assignment to interventions (eg, participants, care providers, outcome assessors, data analysts)	Not reported (open-label educational trial)
	20b	If blinded, how blinding was achieved and description of the similarity of interventions	Not applicable
Statistical methods	21a	Statistical methods used to compare groups for primary and secondary outcomes, including harms	Pages 7-8, Lines 230-273
	21b	Definition of who is included in each analysis (eg, all randomised participants), and in which group	Page8, Lines 282-306
	21c	How missing data were handled in the analysis	Page 8, Lines 282-306
	21d	Methods for any additional analyses (eg, subgroup and sensitivity analyses), distinguishing prespecified from post hoc	Page 8, Lines 282-306
Results			
Participant flow, including flow diagram	22a	For each group, the numbers of participants who were randomly assigned, received intended intervention, and were analysed for the primary outcome	Page 4, Lines 120-122; Diagram 1
	22b	For each group, losses and exclusions aker randomisation, together with reasons	Page 4, Lines 120-122(100% completion; no losses)
Recruitment	23a	Dates defining the periods of recruitment and follow-up for outcomes of benefits and harms	Page 4, Lines 124-134
	23b	If relevant, why the trial ended or was stopped	Not applicable
Intervention and comparator delivery	24a	Intervention and comparator as they were actually administered (eg, where appropriate, who delivered the intervention/comparator, how participants adhered, whether they were delivered as intended (fidelity))	Pages 5-6, Lines 154-199
	24b	Concomitant care received during the trial for each group	Not applicable (educational intervention)
Baseline data	25	A table showing baseline demographic and clinical characteristics for each group	Page 9, Lines 307-318; Table 2
Numbers analysed, outcomes and estimation	26	For each primary and secondary outcome, by group: the number of participants included in the analysis the number of participants with available data at the outcome time point result for each group, and the estimated effect size and its precision (such as 95% confidence interval) for binary outcomes, presentation of both absolute and relative effect size	Pages 9-11, Lines 319-368; Tables 3-5
Harms	27	All harms or unintended events in each group	Not applicable
Ancillary analyses	28	Any other analyses performed, including subgroup and sensitivity analyses, distinguishing pre-specified from post hoc	Not applicable
Discussion			
Interpretation	29	Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence	Pages 11-14, Lines 385-489
Limitations	30	Trial limitations, addressing sources of potential bias, imprecision, generalisability, and, if relevant, multiplicity of analyses	Page 14-15, Lines 490-513

Table 1 Consort Statement